Personal Capital Advisors Corp Trims Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Personal Capital Advisors Corp trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 5.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,607 shares of the medical research company’s stock after selling 7,063 shares during the period. Personal Capital Advisors Corp owned approximately 0.25% of Charles River Laboratories International worth $13,028,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Charles River Laboratories International by 12.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after buying an additional 202 shares during the last quarter. Riverhead Capital Management LLC lifted its stake in Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 247 shares during the last quarter. Cambridge Advisors Inc. purchased a new position in Charles River Laboratories International in the second quarter valued at approximately $202,000. Advisor Partners LLC purchased a new position in Charles River Laboratories International in the second quarter valued at approximately $208,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in Charles River Laboratories International in the second quarter valued at approximately $217,000. 97.27% of the stock is owned by institutional investors and hedge funds.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) traded down $0.73 during midday trading on Friday, hitting $102.12. 1,051,700 shares of the company’s stock were exchanged, compared to its average volume of 380,128. Charles River Laboratories International, Inc. has a fifty-two week low of $69.51 and a fifty-two week high of $119.05. The company has a market capitalization of $4,871.13, a P/E ratio of 20.21, a price-to-earnings-growth ratio of 1.65 and a beta of 0.94. The company has a quick ratio of 1.49, a current ratio of 1.88 and a debt-to-equity ratio of 1.13.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.08. The business had revenue of $464.23 million during the quarter, compared to the consensus estimate of $458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.18 earnings per share. research analysts forecast that Charles River Laboratories International, Inc. will post 5.11 earnings per share for the current year.

WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/11/12/personal-capital-advisors-corp-sells-7063-shares-of-charles-river-laboratories-international-inc-crl.html.

A number of brokerages have issued reports on CRL. Barclays PLC reissued a “hold” rating and set a $102.00 target price on shares of Charles River Laboratories International in a report on Wednesday, July 19th. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. BidaskClub cut shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Robert W. Baird reissued a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a research note on Friday, September 1st. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $120.00 target price on shares of Charles River Laboratories International in a research note on Tuesday, September 12th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Charles River Laboratories International presently has a consensus rating of “Buy” and an average target price of $105.77.

In related news, insider David Ross Smith sold 2,552 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $67.10, for a total value of $171,239.20. Following the sale, the insider now owns 11,671 shares in the company, valued at $783,124.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William D. Barbo sold 4,000 shares of Charles River Laboratories International stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $99.91, for a total transaction of $399,640.00. Following the transaction, the insider now owns 20,424 shares in the company, valued at approximately $2,040,561.84. The disclosure for this sale can be found here. Insiders have sold 18,699 shares of company stock valued at $1,892,393 in the last three months. 2.20% of the stock is owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply